ALK-Abelló A/S (0OIR.IL)
| Previous close | 149.45 |
| Open | 182.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 181.90 - 183.30 |
| 52-week range | 74.45 - 185.50 |
| Volume | |
| Avg. volume | 12,218 |
| Market cap | 30.001B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 92.83 |
| EPS (TTM) | 1.61 |
| Earnings date | 14 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 Mar 2017 |
| 1y target est | N/A |
GlobeNewswireSix-month interim report (Q2) 2024
Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet sales, and improved performance of injection- and drop-based allergy immunotherapy products. ALK’s European and International markets were key contributors to growth. The increase in operating profit (EBIT) of 189% is in-line with ALK’s financial targets. Full-year outlook has been upgraded. Q2 performance
- GlobeNewswire
ALK upgrades its full-year revenue and earnings outlook
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance and outlook for the remainder of the year. Revenue is now expected to grow by 14-16% in local currencies (prev.: 12-15%).The EBIT margin is now expected to improve to 19-21% (prev.: 18-20%) vs. 14% in 2023. The full-year revenue outlook has been upgraded primarily to reflect the strong sales of tablets and injection- and drop-based allergy immunotherapy pro
- GlobeNewswire
Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first six months (Q2) 2024 in the morning of 23 August 2024. Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK’s management will comment on the results for the first six months and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting w
